Clinical utility of an automated immunochemiluminometric thyroglobulin assay in differentiated thyroid carcinoma

Clinical Chemistry

Volumn 52, Issue 4, 2006, Pages 686-691

  Persoon, Adrienne C M ^a   Van Den Ouweland, Johannes M W ^b   Wilde, Juergen ^c,d   Kema, Ido P ^a   Wolffenbuttel, Bruce H R ^a   Links, Thera P ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^c Nichols Institute Diagnostics   (Germany)

^d R Biopharm AG Rhome Ltd Scotland   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

THYROGLOBULIN; THYROGLOBULIN ANTIBODY; THYROTROPIN;

ADULT; ARTICLE; AUTOMATION; CHEMOLUMINESCENCE; CLINICAL PRACTICE; FEMALE; FOLLOW UP; HUMAN; IMMUNOASSAY; IMMUNORADIOMETRIC ASSAY; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; REPRODUCIBILITY; THYROID CARCINOMA; THYROIDECTOMY; THYROTROPIN BLOOD LEVEL;

AUTOANALYSIS; CHEMILUMINESCENT MEASUREMENTS; FEMALE; HUMANS; IMMUNOASSAY; MALE; MIDDLE AGED; THYROGLOBULIN; THYROID NEOPLASMS;

EID: 33645452491     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2005.060095     Document Type: Article

References (23)

1. Herle van AJ, Vassart G, Dumont JE. Control of thyroglobulin synthesis and secretion (second of two parts). N Engl J Med 1979;301:307-14.
2. Spencer CA, Wang C-C. Thyroglobulin measurement, techniques, clinical benefits, and pitfalls. Endocrinol Metab Clin North Am 1995;24:841-63.
3. Baloch Z, Carayon P, Conte-Devolx B, Demers LM, Feldt-Rasmussen U, Henry JF, et al. Laboratory medicine practice guidelines: laboratory support for the diagnosis and monitoring of thyroid disease. Thyroid 2003;13:57-67.
4. Spencer CA, Takeuchi M, Kazarosyan M, Wang CC, Guttler RB, Singer PA, et al. Serum thyroglobulin autoantibodies: prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 1998;83:1121-7.
5. Preissner CM, O'Kane DJ, Singh RJ, Morris JC, Grebe SK. Phantoms in the assay tube: heterophilic antibody interferences in serum thyroglobulin assays. J Clin Endocrinol Metab 2003;88:3069-74.
6. Iervasi A, Iervasi G, Bottoni A, Boni G, Annicchiarico C, Di Cecco P, et al. Diagnostic performance of a new highly sensitive thyroglobulin immunoassay. J Endocrinol 2004;182:287-94.
7. 131I with regard to surgery in patients with differentiated thyroid carcinoma. Cancer 2005;103:59-67.
8. Hermanek P, Sobin LH, eds. TNM classification of malignant tumours, 4th ed, 2nd revision. Berlin: Springer-Verlag, 1992:35-7.
9. Mazzaferri EL, Massoll N. Management of papillary and follicular (differentiated) thyroid cancer: new paradigms using recombinant human thyrotropin. Endocr Relat Cancer 2002;9:227-47.
10. 131I therapy useful? J Endocrinol Invest 2001;24:194-8.
11. Schlumberger M, Pacini F, Wiersinga WM, Toft A, Smit JW, Sanchez Franco F, et al. Follow-up and management of differentiated thyroid carcinoma: a European perspective in clinical practice. Eur J Endocrinol 2004;151:539-48.
12. Mazzaferri EL, Robbins RJ, Spencer CA, Braverman LE, Pacini F, Wartofsky L, et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 2003;88:1433-41.
13. Bachelot A, Cailleux AF, Klain M, Baudin E, Ricard M, Bellon N, et al. Relationship between tumor burden and serum thyroglobulin level in patients with papillary and follicular thyroid carcinoma. Thyroid 2002;12:707-11.
14. Eustatia-Rutten CFA, Smit JWA, Romijn JA, van der Kleij-Corssmit EPM, Pereira AM, Stokkel MP, et al. Diagnostic value of serum thyroglobulin measurements in the follow-up of differentiated thyroid carcinoma, a structured meta-analysis. Clin Endocrinol 2004;61:61-74.
15. Spencer CA, Takeuchi M, Kazarosyan M. Current status and performance goals for serum thyroglobulin assays. Clin Chem 1996;42:164-73.
16. Spencer CA, Bergoglio LM, Kazarosyan M, Fatemi S, LoPresti JS. Clinical impact of thyroglobulin (Tg) and Tg autoantibody method differences on the management of patients with differentiated thyroid carcinomas. J Clin Endocrinol Metab 2005;90:5566-75.
17. Mazzaferri EL, Kloos RT. Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation? J Clin Endocrinol Metab 2002;87:1490-8.
18. Baudin E, Do Cao C, Cailleux AF, Leboulleux S, Travagli JP, Schlumberger M. Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients. J Clin Endocrinol Metab 2003;88:1107-11.
19. Pacini F, Molinaro E, Lippi F, Castagna MG, Agate L, Ceccarelli C, et al. Prediction of disease status by recombinant human TSH-stimulated serum Tg in the postsurgical follow-up of differentiated thyroid carcinoma. J Clin Endocrinol Metab 2001;86:5686-90.
20. Zöphel K, Wunderlich G, Smith BR. Serum thyroglobulin measurements with a high sensitivity enzyme-linked immunosorbent assay: is there a clinical benefit in patients with differentiated thyroid carcinoma? Thyroid 2003;9:861-5.
21. Stockigt JR. Ambiguous thyroglobulin assay results in the follow-up of differentiated thyroid carcinoma [Editorial]. J Clin Endocrinol Metab 2005;90:5904-5.
22. Brendel AJ, Lambert B, Guyot M, Jeandot R, Dubourg H, Roger P, et al. Low levels of serum thyroglobulin after withdrawal of thyroid suppression therapy in the follow up of differentiated thyroid carcinoma. Eur J Nucl Med 1990;16:35-8.
23. 131I whole-body scanning. J Nucl Med 2005;46:1473-80.